Spots Global Cancer Trial Database for Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Official Title: A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Study ID: NCT01579994
Conditions
Interventions
Study Description
Brief Summary: About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients take part in the study. The study will only be open at Memorial Sloan Kettering Cancer Center.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States
Contact Details
Name: Gregrory Riely, MD, PhD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
